Martin Merschhemke

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 700 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Fred Lublin, David H. Miller, Mark S. Freedman et al. · The Lancet · 2016 · 449 citations · Full text

Medicine, Neurology, Pharmacotherapy +10

A new clinico-pathological classification system for mesial temporal sclerosis

Ingmar Blümcke, E. Pauli, Hans Clusmann et al. · Acta Neuropathologica · 2007 · 350 citations · Full text

Medicine, Neurology, Neuroscience +16

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

Tanuja Chitnis, Douglas L. Arnold, Brenda Banwell et al. · New England Journal of Medicine · 2018 · 326 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +12

Hemodynamic correlates of epileptiform discharges: An EEG-fMRI study of 63 patients with focal epilepsy

Afraim Salek‐Haddadi, Beate Diehl, Khalid Hamandi et al. · Brain Research · 2006 · 279 citations

Medicine, Neurology, Neuroscience +17